Your AI-Trained Oncology Knowledge Connection!
A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.
Heloisa P. Soares, MD, PhD, discusses recent developments in NETS, pancreatic cancer, and GEJ tumors, as well as sequencing strategies aimed at improving patient outcomes across GI cancers.
Six months after receiving a second dose of the Pfizer-BioNTech COVID-19 vaccine, patients with solid tumors retained similar levels of COVID-19 antibodies in their blood as individuals without cancer.
The FDA has approved brexucabtagene autoleucel as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
The Augusta University community is encouraged to participate in this year’s Paceline bicycle ride on October 16.
Although adjuvant targeted therapy options are reserved for patients with EGFR-mutated non–small cell lung cancer, molecular testing is a critical step in the treatment of all patients with metastatic disease, where multiple driver mutations are associated with FDA-approved therapeutics.
The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.
A supplemental biologics license application has been submitted to the FDA to expand the current indication of the CAR T-cell therapy axicabtagene ciloleucel to include the second-line treatment of adult patients with relapsed/refractory large B-cell lymphoma.
The understanding of EGFR signaling in non–small cell lung cancer continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations.
Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.
Rovalpituzumab tesirine failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer, warranting its discontinued development.
Epcoritamab had a manageable toxicity profile when subcutaneously administered to patients with relapsed/refractory B-cell non-Hodgkin lymphoma and was found to elicit encouraging responses in those who were heavily pretreated.
Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.
The National Institute for Clinical Excellence has issued final guidance supporting the use of atezolizumab for patients with treatment-naïve, PD–L1–positive locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin.
The FDA has granted a priority review designation to a new drug application for lutetium-177-PSMA-617 for use in the treatment of patients with metastatic castration-resistant prostate cancer following androgen receptor pathway inhibition and taxane-based chemotherapy.
Cleveland Clinic has established a center focused on the diagnosis, care, and research of young-onset colorectal cancer.
Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.
Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.
Kanwal P.S. Raghav, MBBS, MD, discussed nuances to treatment selection in mCRC, the significance of the phase 2 ReDOS trial with regorafenib, and how the paradigms for mCRC, HCC, and gastroesophageal cancers have expanded from areas of unmet need to ones with more robust armamentariums.
The FDA has granted a fast track designation to the first-in-class nucleotide analogue NUC-1031 for use as a potential therapeutic option in the frontline treatment of patients with advanced biliary tract cancer.
Health Canada has approved infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.
Sarah Cannon recently opened its newest drug development unit in collaboration with Florida Cancer Specialists & Research Institute and The University of Central Florida College of Medicine in Lake Nona, Flordia.
Cabozantinib demonstrated a sustained benefit in progression-free survival vs placebo in patients with previously treated, radioactive iodine–refractory differentiated thyroid cancer, regardless of prior exposure to sorafenib or lenvatinib.
Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.
Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.
The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.
The FDA has granted approval of a new indication for cetuximab plus encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by a FDA-approved test, after prior therapy.
Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.
Sandra Duncan, RN, BSN, shares her experience with the CheckMate-73L trial of ipilimumab/nivolumab in non–small cell lung cancer, efforts made to overcome communication challenges, and the importance of nurse coordinators in the realm of clinical trials.
The investigational next-generation ROS1/NTRK inhibitor taletrectinib was found to elicit encouraging responses with an acceptable toxicity profile in patients with ROS1-positive non–small cell lung cancer, according to preliminary data from the phase 2 TRUST trial.
